Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • Rights and Permissions
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • My alerts
  • Log in
  • Log out
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • Rights and Permissions
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Cutting Edge: Productive HIV-1 Infection of Dendritic Cells via Complement Receptor Type 3 (CR3, CD11b/CD18)

Zsuzsa Bajtay, Cornelia Speth, Anna Erdei and Manfred P. Dierich
J Immunol October 15, 2004, 173 (8) 4775-4778; DOI: https://doi.org/10.4049/jimmunol.173.8.4775
Zsuzsa Bajtay
Department of Hygiene, Microbiology and Social Medicine, Innsbruck Medical University and Ludwig-Boltzman-Institute for AIDS Research, Innsbruck, Austria; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cornelia Speth
Department of Hygiene, Microbiology and Social Medicine, Innsbruck Medical University and Ludwig-Boltzman-Institute for AIDS Research, Innsbruck, Austria; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Erdei
Department of Immunology and Research Group of the Hungarian Academy of Sciences, Eötvös Loránd University, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manfred P. Dierich
Department of Hygiene, Microbiology and Social Medicine, Innsbruck Medical University and Ludwig-Boltzman-Institute for AIDS Research, Innsbruck, Austria; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

In the present study, we demonstrate that macrophage-tropic HIV-1 opsonized by complement and limited amounts of anti-HIV-IgG causes up to 10-fold higher productive infection of human monocyte-derived dendritic cells than HIV treated with medium or HIV opsonized by Ab only. Enhanced infection is completely abolished by a mAb specific for the ligand-binding site of CD11b (i.e., α-chain of complement receptor 3, receptor for iC3b), proving the importance of complement receptor 3 in this process. Inhibition of complement activation by EDTA also prevents enhanced infection, further demonstrating the role of complement in virus uptake and productive infection. Since HIV is, even in the absence of Abs, regularly opsonized by complement, most probably the above-described mechanism plays a role during in vivo primary infection.

Effector functions of the complement system, one of the main components of natural immunity, include opsonization leading to enhanced phagocytosis and lysis of microbes. HIV is able to activate complement both in the absence and, even more so, in the presence of virus-specific Abs. Following binding of C1q to gp41 of HIV, the classical pathway of complement activation is initiated (1), while the lectin-dependent activation is initiated by the interaction of gp120 and gp41 with the mannan-binding lectin (2). Covalent binding of C3 fragments to the viral envelope allows binding of HIV to cells expressing receptors for C3b (complement receptor (CR)2 1, CD35), iC3b (CR3, CD11b/CD18; CR4, CD11c/CD18), and C3d, C3dg (CR2, CD21). HIV-1 infection of human lymphocytes and monocytes/macrophages is greatly enhanced by opsonization of the virus with complement (3, 4, 5).

In general, microorganisms coated with C3 fragments acquire the capacity for high binding to CR1–4 (3, 4, 5, 6, 7). CR3 and CR4 are members of the β2-integrin family, are expressed on several cell types, including phagocytic cells, and play an important role in phagocytosis of opsonized pathogens. It has been shown that dendritic cells (DCs) in normal human skin as well as monocyte-derived DCs (MDCs) differentiated in vitro express CD11b (8). Regarding the expression of CD11c, two major populations are present in the body: the CD11c+ myeloid DCs, and the CD11c− plasmacytoid DCs. CR3 and adhesion molecules are documented to facilitate viral entry into different target cells (9, 10).

CD14+ human monocytes can develop into MDCs in vitro by culturing in medium containing GM-CSF and IL-4. By day 5 in culture, the cells have the characteristics of immature DCs (imMDCs) and can be further induced to mature DCs by inflammatory stimulus such as LPS. Maturation rapidly induces DCs to express costimulatory molecules, such as CD80 and CD86, necessary for the activation of naive T cells (11). Targets of HIV during primary in vivo infection are macrophages and DCs, which are predominantly permissive for R5 viruses (12). imMDCs can be productively infected with R5 viruses and the virus produced by these cells is able to infect T cells. Mature DCs do not produce viral particles, still they are able to transmit both R5 and X4 viruses to T cells (13).

Our observation that complement opsonization of HIV causes a distinctively productive infection of DCs has not yet been documented. In this study, we report that CR3 plays a crucial role in the productive infection of imMDCs by C3-opsonized HIV.

Materials and Methods

Media, Abs, cytokines

Anti-human (hu) C3c, anti-huC3d, and anti-huIgG rabbit polyclonal Abs and FITC-conjugated goat anti-mouse Ig polyclonal Ab were obtained from DakoCytomation (Glostrup, Denmark). Mouse mAbs used in this work were as follows: anti-CD4, anti-CD86, anti-CD83, anti-CD14, anti-CCR5, anti-CD11c (BD Pharmingen, San Diego, CA) anti-CD18 (OKM-1); hybridoma supernatants and mouse IgG1 isotype control were used at 10 μg/ml. mAb TMG6-5 blocking anti-CD11b (14) was kindly provided by I. Andó (Biological Research Center, Szeged, Hungary).

DC cultures

MDCs were generated in vitro by culturing monocytes (15, 16). Briefly, PBMCs were obtained by the standard Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden) method. Monocytes were isolated by adherence using gelatin-coated petri dishes (17). The purity of the monocyte suspension was 90–95%, as judged by FACS analysis. Differentiation of monocytes into imMDCs was induced by culturing in RPMI 1640 medium (Invitrogen Life Technologies, Grand Island, N.Y.) supplemented with 1600 U/ml recombinant human (rh) GM-CSF (Novartis, Vienna, Austria), and 1500 U/ml rhIL-4 (PromoCell, Heidelberg, Germany), 10% heat-inactivated FCS (Invitrogen Life Technologies), 2 mM l-glutamine, and 50 μg/ml gentamicin (Sigma-Aldrich, St. Louis, MO) in 24-well tissue culture plates (Costar, Cambridge, MA). Culture medium was refreshed at days 5 and 7 and supplemented with cytokines at days 2, 5, and 7. imMDCs were CD14−, CD80+, CD86+, CD83−, CD11b+, CD11c+, HLA-DR+, CD4low, and CCR5low (12, 18). imMDCs were used for virus binding and infectious experiments on day 7 of culture. Occasionally, in vitro maturation of MDCs was induced by 100 ng/ml LPS (Sigma-Aldrich).

HIV sources, p24 ELISA

The M-tropic HIV-1 primary isolate 92UG037 (subtypeA/A, R5 tropism) was kindly provided by G. Stiegler (Institute of Applied Microbiology, Vienna, Austria). Virus stock was produced by PHA-activated PBMCs of healthy donors and maintained in RPMI 1640 supplemented with 10% FCS, 2 mM l-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. The virus was pelleted at 20,000 rpm by ultracentrifugation and stored at −80°C. For assessment of virus quantity, the p24 capture ELISA was used, developed at the Institute of Applied Microbiology in Vienna (19); it was performed as described earlier (18).

Opsonization of HIV, virus capture assay

Opsonized virus was prepared in the presence of anti-HIV IgG (purified from pooled sera of HIV+ patients) and normal human serum as complement source (HIVIgG + C) or in the presence of anti-HIV IgG alone (HIVIgG). Control samples were prepared in medium only (HIV). For opsonization, 1 μg/ml p24 HIV was incubated with 50 μg/ml anti-HIV IgG (HIVIgG) or with anti-HIV IgG and 10-fold diluted normal human serum (HIVIgG + C) for 1 h at 37°C. In some experiments, EDTA (20 mM) was used to inhibit complement activation (HIVIgG + C + EDTA). The opsonized virus was washed and pelleted by ultracentrifuge; aliquots were stored at −80°C and thawed once before the experiments. Opsonization was detected by a virus capture ELISA system. Preparations containing opsonized HIV were incubated in wells coated by Abs specific for huIgG, or for complement fragments C3c and C3d, respectively. Captured HIV was lysed in detergent and transferred to anti-p24-coated plates. After incubation with anti-HIV IgG, the virus bound intensively to the anti-IgG coat. As a result of classical pathway activation of the complement system, strong C3 and low (if any) IgG deposition were detected in the HIVIgG + C samples, suggesting poor accessibility of the IgG on HIVIg + C.

Binding of HIV to DC

To demonstrate binding of HIV, 5 × 105 imMDCs were incubated with 10 ng/ml p24 HIV, HIVIgG, HIVIgG + C, and HIVIgG + C + EDTA for 1 h at 37°C. Then nonbound virus was removed by washing two times with warm medium. The cells were lysed with 1% Nonidet P-40 and the amount of p24 Ag was determined by p24 ELISA. To determine the effect of proteinase K (Sigma-Aldrich) on HIV entry, the cells were held in the presence of 10 μg/ml enzyme before determination of p24. All data are presented as mean values ± SD.

Infection of MDCs with HIV-1

To determine the infectivity of HIV, 5 × 105 imMDCs were incubated with 10 ng/ml p24 HIV, HIVIgG, HIVIgG + C, and HIVIgG + C + EDTA, respectively, for 8 h, then the cells were washed two times with warm medium and placed back into culture in 24-well plates for an additional 15 days. Twenty-five percent of medium was replaced with rhIL-4 and rhGM-CSF every third day. The amount of virus produced by the cells was estimated by p24 ELISA from the supernatants every other day.

Flow cytometry

The expression of surface molecules of cells was determined at day 7 of culture. Briefly, 5 × 104 cells were washed with 1% BSA-0,1% NaN3-PBS and incubated with Abs reacting with CD80, CD86, CD83, CD11b, CD11c, CD18, HLA-DR, CD14, CD4, and CCR5, followed by FITC-labeled anti-mouse IgG. As control, samples were labeled with isotype-matched control Abs. After staining, the cells were washed and fixed in PBS containing 1% Formalin and 0,1% NaN3 and analyzed by flow cytometry (FACScan; BD Biosciences, Mountain View, CA).

Results

Expression of CR3 during maturation of DCs

It has been demonstrated in earlier studies that DCs do not possess CR1 and CR2, while they express CR3 and CR4 (18, 20, 21). Since opsonization is known to influence viral infection (4, 5, 22) we aimed to clarify whether CR3, mediating the uptake of C-coated particles by several cell types, is involved in a similar process of MDCs. For these experiments we used the Ab TMG6-5, which interacts with the receptor’s ligand binding site. Fig. 1⇓ shows that TMG6-5 binds to imMDCs and mature MDCs (maMDCs) in a similar fashion. It is also seen in Fig. 1⇓ that the percentage of CR3+ cells is decreased in maMDCs.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Surface expression of CD11b and CD18 of imMDCs and maMDCs at day 7. Shaded histograms represent the binding of CD11b- and CD18-specific Abs. Open histograms represent isotype-matched controls. Mean fluorescence intensity values are shown. The data are representative of seven independent experiments.

Effect of opsonization by complement on binding of HIV-1 to imMDCs

To investigate the binding of C-opsonized HIV, imMDCs were incubated with HIVIgG + C and for control with HIV, HIVIgG, and HIVIgG + C + EDTA. After removing nonbound virus, cells were lysed and the amount of p24 Ag was determined by ELISA. Fig. 2⇓ shows that HIVIgG + C binds more efficiently to imMDCs than HIVIgG. This enhancement was abolished when complement activation and opsonization were inhibited by 20 mM EDTA.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Binding of nonopsonized and opsonized HIV to imMDCs. imMDCs at day 7 were incubated with HIV, HIVIgG, HIVIgG + C, and HIVIgG + C + EDTA for 1 h at 37°C. The concentration of p24 Ag was determined from the cell lysates after removing nonbound viruses. The data are representative of six independent experiments.

Effect of opsonization of HIV by complement on infection of imMDCs

Infection of human monocytes and macrophages with HIV is greatly facilitated by opsonization of the virus with C3 fragments (5, 22). To test whether infection of imMDCs by HIV is influenced by opsonization, the cells were cultured with the HIV-1 primary isolate pretreated with IgG and complement. Culture supernatants were collected every other day, centrifuged, and the concentration of free virions was estimated by p24 ELISA. As demonstrated in Fig. 3⇓, opsonization with HIV-specific IgG and human complement caused >10-fold enhancement in HIV production by MDCs, as compared with nonopsonized HIV or HIV opsonized with specific IgG only. Virus particles treated with serum in the presence of 20 mM EDTA caused low productive infection similar to the medium-treated control.

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

Productive infection of imMDCs by opsonized HIV-1. imMDCs were infected with HIV, HIVIgG, HIVIgG + C, and HIVIgG + C + EDTA at day 7. The amount of free virions was measured by p24 ELISA from the supernatants on days as indicated. The data are representative of five independent experiments.

Treatment of imMDCs with CD11b-specific Ab or with proteinase K and their effect on infection by complement-opsonized HIV-1

To investigate the role of CR3 in the uptake of the opsonized virus, the cells were preincubated with mAb TMG6-5, which interacts with the ligand binding site of CD11b. As shown in Fig. 4A⇓, the Ab reduced binding of HIVIgG + C to background level. Also, as seen in Fig. 4⇓B, the productive infection of MDCs tested on day 14 was almost completely abolished by the CR3-specific Ab, while the isotype-matched control Ab showed no effect. To demonstrate that uptake of opsonized HIV was the key to productive infection, cells were treated with proteinase K before p24 measurement. As shown in Fig. 4⇓A, this enzyme treatment resulted in a significant loss of HIV associated with MDCs.

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

The effect of anti-CD11b mAb (TMG6-5) and proteinase K on binding of opsonized HIV and productive infection of imMDCs. A, imMDCs, pretreated with mAb TMG6-5 and, as control, with isotype-matched control Ab were incubated with HIVIgG + C. The effect of proteinase K was assessed after treating the cells in the presence of 10 μg/ml enzyme. The amount of p24 Ag was determined by p24 ELISA. All data are presented as mean values ± SD. B, To determine infectivity of imMDCs pretreated with mAb TMG6-5 and, as control, with isotype-matched control Ab were incubated with HIVIgG + C, and cells were placed back into culture after washing. The amount of virus produced by the cells was estimated by p24 ELISA from the supernatants on days as indicated. The data are representative of five independent experiments.

Discussion

It is generally accepted that opsonization by complement enhances HIV uptake by CR-bearing cells, including MDCs. In this study, we show that opsonization of HIV with complement (and IgG) caused a slight increase in binding to MDCs but a 10-fold higher productive infection of imMDCs. This describes for the first time the crucial role of CR3 in this process. In contrast to CR3, DC-specific ICAM-3-grabbing nonintegrin, another important attachment receptor for HIV on DCs, is known to bind HIV and to operate in transmission of the virus to CD4+ T cells (23); however, this does not induce productive infection of DCs. The key role of CR3 in efficient uptake of opsonized HIV by imMDCs was proven by inhibition with CD11b-specific mAbs. We also found that productive infection was strongly inhibited by anti-CD4 mAb (data not shown), suggesting that even in CR3-mediated enhancement of productive infection CD4 plays a critical role. In other studies, inhibition by anti-CR3 mAb of monocyte infection (18, 22) and partial inhibition by CD11b-specific Abs (10) of PBMC infection with HIV were observed.

Opsonization of HIV by complement occurs in human serum by direct binding of C1q already in the absence of anti-HIV Abs (1, 2), but is much more pronounced after binding of Abs on the surface of HIV. Complement is also known to be activated by HIV upon direct binding of MBL; the activation of the alternative pathway in HIV-infected patients has also been observed (24). Other studies, however, show that intact HIV activates complement only in the presence of antiviral Abs (25, 26). Sensitivity to complement-mediated lysis is influenced by the actual composition of the viral membrane, as in vitro studies demonstrated that some primary isolates of HIV are highly resistant to complement-mediated lysis due to the incorporation of host cell-derived complement control proteins, including CD46, CD55, and CD59 (27, 28).

Since HIV particles in infected patients are early on coated with complement at the site of infection, imDCs could be the first target of infection. As reported by Shi et al. (29), clustering of CR3 on monocytic cells recruits a Toll/IL-1R family-like signaling cascade, interacting with IL-1R-associated kinase 1 to induce NF-κB activity. HIV opsonized with C3 fragments represents a multimerized ligand. In our studies its binding most probably leads to clustering of CR3 and thus supports NF-κB signaling. This may then direct regulation of genes encoding for cytokines, chemokines, adhesion molecules, and enzymes, thereby modulating several cellular functions.

Although the precise mechanism through which complement coating of HIV leads to a 30% increase in HIV binding to CR3 on imMDCs but to a 10-fold increase in virus production remains unclear. The following hypothesis may be offered: Binding of complement-coated HIV to CR3 may induce specific signaling cascades and direct HIV to compartments in DCs which are favorable for productive infection. Both aspects are subjects of future research.

Acknowledgments

We thank C. Larcher for helpful discussion and the Austrian Research Fond (FWF, P15379, and P15375), the state of Tyrol, and the Ludwig-Boltzmann Society for support.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 Address correspondence and reprint requests to Prof. Manfred P. Dierich, Department of Hygiene, Microbiology and Social Medicine, Innsbruck Medical University and Ludwig-Boltzman-Institute for AIDS Research, Fritz-Pregl-Strasse 3, A-6020 Innsbruck, Austria. E-mail address: hygiene{at}uibk.ac.at

  • ↵2 Abbreviations used in this paper: CR, complement receptor; DC, dendritic cell; MDC, monocyte-derived DC; imMDC, immature MDC; hu, human; rh, recombinant human; maMDC, mature MDC.

  • Received June 8, 2004.
  • Accepted August 18, 2004.
  • Copyright © 2004 by The American Association of Immunologists

References

  1. ↵
    Ebenbichler, C. F., N. M. Thielens, R. Vornhagen, P. Marschang, G. J. Arlaud, M. P. Dierich. 1991. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J. Exp. Med. 174:1417.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Dierich, M. P., C. F. Ebenbichler, P. Marschang, G. Fust, N. M. Thielens, G. J. Arlaud. 1993. HIV and human complement: mechanisms of interaction and biological implication. Immunol. Today 14:435.
    OpenUrlCrossRefPubMed
  3. ↵
    Delibrias, C. C, M. D. Kazatchkine, E. Fischer. 1993. Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV. Scand. J. Immunol. 38:183.
    OpenUrlCrossRefPubMed
  4. ↵
    Legendre, C., G. Gras, R. Krzysiek, P. Galanaud, Y. Richard, D. Dormont. 1996. Mechanisms of opsonized HIV entry in normal B lymphocytes. FEBS Lett. 381:227.
    OpenUrlCrossRefPubMed
  5. ↵
    Thieblemont, N., N. Haeffner-Cavaillon, A. Ledur, J. L’Age-Stehr, H. W. Ziegler-Heitbrock, M. D. Kazatchkine. 1993. CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin. Exp. Immunol. 92:106.
    OpenUrlPubMed
  6. ↵
    Erdei, A., G. Füst, J. Gergely. 1991. The role of C3 in the immune response. Immunol. Today 12:332.
    OpenUrlCrossRefPubMed
  7. ↵
    Gordon, S.. 2002. Pattern recognition receptors: doubling up for the innate immune response. Cell 111:927.
    OpenUrlCrossRefPubMed
  8. ↵
    Grassi, F., C. Dezutter-Dambuyant, D. McIlroy, C. Jacquet, K. Yoneda, S. Imamura, L. Boumsell, D. Schmitt, B. Autran, P. Debre, A. Hosmalin. 1998. Monocyte-derived dendritic cells have a phenotype comparable to that of dermal dendritic cells and display ultrastructural granules distinct from Birbeck granules. J. Leukocyte Biol. 64:484.
    OpenUrlAbstract
  9. ↵
    Hildreth, J. E., R. J. Orentas. 1989. Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. Science 244:1075.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Stoiber, H., I. Frank, M. Spruth, M. Schwendinger, B. Mullauer, J. M. Windisch, R. Schneider, H. Katinger, I. Ando, M. P. Dierich. 1997. Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry?. Mol. Immunol. 34:855.
    OpenUrlCrossRefPubMed
  11. ↵
    Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767.
    OpenUrlCrossRefPubMed
  12. ↵
    Zaitseva, M., A. Blauvelt, S. Lee, C. K. Lapham, V. Klaus-Kovtun, H. Mostowski, J. Manischewitz, H. Golding. 1997. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat. Med. 3:1369.
    OpenUrlCrossRefPubMed
  13. ↵
    Granelli-Piperno, A, E. Delgado, V. Finkel, W. Paxton, R. M. Steinman. 1998. Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J. Virol. 72:2733.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Uciechowski, P., R. E. Schmidt. 1989. White cell differentiation antigens. W. Knapp, and B. Dörken, and W. R. Gilks, and E. P. Rieber, and R. E. Schmidt, and H. Stein, and A. E. G. von dem Borne, eds. Leukocyte Typing IV 543. Oxford Univ. Press, Oxford, U.K..
  15. ↵
    Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P. O. Fritsch, R. M. Steinman, G. Schuler. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Sallusto, F., A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179:1109.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Freundlich, B., N. Avdalovic. 1983. Use of gelatin/plasma coated flasks for isolating human peripheral blood monocytes. J. Immunol. Methods 62:31.
    OpenUrlCrossRefPubMed
  18. ↵
    Kacani, L., I. Frank, M. Spruth, M. G. Schwendinger, B. Mullauer, G. M. Sprinzl, F. Steindl, M. P. Dierich. 1998. Dendritic cells transmit human immunodeficiency virus type 1 to monocytes and monocyte-derived macrophages. J. Virol. 72:6671.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Purtscher, M., A. Trkola, G. Gruber, A. Buchacher, R. Predl, F. Steindl, C. Tauer, R. Berger, N. Barrett, A. Jungbauer. 1994. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10:1651.
    OpenUrlCrossRefPubMed
  20. ↵
    Hart, D. N., J. L. McKenzie. 1988. Isolation and characterization of human tonsil dendritic cells. J. Exp. Med. 168:157.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Stingl, G., E. C. Wolff-Schreiner, W. J. Pichler, F. Gschnait, W. Knapp, K. Wolff. 1977. Epidermal Langerhans cells bear Fc and C3 receptors. Nature 268:245.
    OpenUrlCrossRefPubMed
  22. ↵
    Bouhlal, H., J. Galon, M. D. Kazatchkine, W. H. Fridman, C. Sautes-Fridman, N. Haeffner Cavaillon. 2001. Soluble CD16 inhibits CR3 (CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1. J. Immunol. 166:3377.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Geijtenbeek, T. B., S. J. van Vliet, A. Engering, B. A. ’t Hart, Y. van Kooyk. 2004. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu. Rev. Immunol. 22:33.
    OpenUrlCrossRefPubMed
  24. ↵
    Yefenof, E., T. Magyarlaki, E. M. Fenyo, B. Wahren, E. Klein. 1994. Alternative complement pathway activation by CD4+ T cells of HIV infected individuals: a possible role in AIDS pathogenesis. Int. Immunol. 6:1361.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    June, R. A., S. Z. Schade, M. J. Bankowski, M. Kuhns, A. McNamara, T. F. Lint, A. L. Landay, G. T. Spear. 1991. Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS 5:269.
    OpenUrlCrossRefPubMed
  26. ↵
    Sullivan, B. L., E. J. Knopoff, M. Saifuddin, D. M. Takefman, M. N. Saarloos, B. E. Sha, G. T. Spear. 1996. Susceptibility of HIV-1 plasma virus to complement-mediated lysis: evidence for a role in clearance of virus in vivo. J. Immunol. 157:1791.
    OpenUrlAbstract
  27. ↵
    Stoiber, H., C. Speth, M. P. Dierich. 2003. Role of complement in the control of HIV dynamics and pathogenesis. Vaccine 21:(Suppl. 2):77. Review.
    OpenUrlCrossRef
  28. ↵
    Montefiori, D. C., R. J. Cornell, J. Y. Zhou, J. T. Zhou, V. M. Hirsch, P. R. Johnson. 1994. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205:82.
    OpenUrlCrossRefPubMed
  29. ↵
    Shi, C., X. Zhang, Z. Chen, M. K. Robinson, D. I. Simon. 2001. Leukocyte integrin Mac-1 recruits Toll/interleukin-1 receptor superfamily signaling intermediates to modulate NF-κB activity. Circ. Res. 89:859.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Immunology: 173 (8)
The Journal of Immunology
Vol. 173, Issue 8
15 Oct 2004
  • Table of Contents
  • About the Cover
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cutting Edge: Productive HIV-1 Infection of Dendritic Cells via Complement Receptor Type 3 (CR3, CD11b/CD18)
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
Citation Tools
Cutting Edge: Productive HIV-1 Infection of Dendritic Cells via Complement Receptor Type 3 (CR3, CD11b/CD18)
Zsuzsa Bajtay, Cornelia Speth, Anna Erdei, Manfred P. Dierich
The Journal of Immunology October 15, 2004, 173 (8) 4775-4778; DOI: 10.4049/jimmunol.173.8.4775

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cutting Edge: Productive HIV-1 Infection of Dendritic Cells via Complement Receptor Type 3 (CR3, CD11b/CD18)
Zsuzsa Bajtay, Cornelia Speth, Anna Erdei, Manfred P. Dierich
The Journal of Immunology October 15, 2004, 173 (8) 4775-4778; DOI: 10.4049/jimmunol.173.8.4775
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cutting Edge: Involvement of the Immunoreceptor CD300c2 on Alveolar Macrophages in Bleomycin-Induced Lung Fibrosis
  • Cutting Edge: TCR Signal Strength Regulates Acetyl-CoA Metabolism via AKT
  • Cutting Edge: Elevated Glycolytic Metabolism Limits the Formation of Memory CD8+ T Cells in Early Life
Show more CUTTING EDGE

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • Public Access
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2019 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606